Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) dropped 1.9% during mid-day trading on Tuesday. The stock traded as low as C$14.00 and last traded at C$14.00. 7,217 shares were traded during mid-day trading, an increase of 307% from the average session volume of 1,775 shares. The stock had previously closed at C$14.28.
Neuren Pharmaceuticals Price Performance
The company’s fifty day moving average price is C$14.79 and its 200 day moving average price is C$11.63.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on developing treatments for serious neurodevelopmental disorders. Based in Melbourne, the company’s research centers on therapies intended to address conditions with limited treatment options.
Its lead partnered medicine, trofinetide, is marketed in the United States by Acadia Pharmaceuticals as DAYBUE for Rett syndrome. Neuren developed the drug and licensed commercialization rights to Acadia.
Neuren is also developing NNZ-2591, an investigational treatment being studied for several neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, Angelman syndrome and Prader-Willi syndrome.
Featured Articles
- Five stocks we like better than Neuren Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
